Pain Models Workshop

P.Danjou, MD,PhD,MAPS -Paris WS 5.b




International Association for the Study of Pain: definition 1994

« An unpleasant **sensory** <u>and</u> **emotional** experience associated with actual or potential tissue damage, or described in terms of such damage »



Different pain syndromes, different pathophysiology



Different time constants and psychological consequences

| Type of evolution | Duration | Psychological states associated | Model of therapeutic intervention |
|-------------------|--|---------------------------------|-----------------------------------|
| Acute Pain | Reasonably related to the affection less than 3 months | Anxiety | Medical, Pasteurian |
| Chronic Pain | Greater than 3 months | Depression | Bio-Psycho-Social |



Development of Pain Medications prior to Phase IIb

Relatively easily modelised

- Acute pain (both animals and humans)
- Inflammatory pain (animals > humans)

Modelised with more difficulties

- Neuropathic pain (animals> humans*)
- -Visceral pain (animals >>humans, in some cases similarities)

Impossible to modelise

- Dysfunctional pain (e.g. fibromyalgia), Complex Regional Pain Syndromes (algodystrophy,causalgia)
- Interactions with anxiety and depression



Types of medical indications in labeling

Pain of mild to moderate intensity

Treatment moderate to severe pain

Neuropathic pain

Postherpetic Neuralgia

Painfull diabetic neuropathy

Trigeminalgia, cluster headache

Treatment of breakthrough pain in non opiate naives

Chronic cancer pain

Acute migraine

Prevention of migraine

Simple headache

Spasmolytic


Some rhumatological indications for NSAIDs

Local anaesthesic



WHO Ladder


For oral medications





Theoretically progressive but clinical sense needed, not all level 1 equivalent

Anatomy of Pain and Emotions



A few of animal models: read=behaviour

| Acute Pain | | Chronic | |
|--|--|---------------|---|
| Paw tests (thresholds) [phasic pain] | Tail Flick Randall-Sellito Hot plate | Inflammatory | Carraghenan paw oedema Freund's adjuvant paw oedema Air pouch in back UV erythema |
| Paw (injection) [tonic pain] | Formalin Capsaicin Bee venom | Neuropathic > | Chemical: Capsaicin Streptozotocin Vincristine Nerves ligation: Chung Seltzer Bennet Spare nerve Injury |
| Visceral | Acetic acid writhing test Barostat | | BIOTRIAL |
| | | | |

A few of Human models: read= subject perception n=20 cross-over

| Acute Pain | | Chronic | |
|--------------|--|-------------------|---|
| (Thresholds) | -Thermal pain -Mechanical pain (electronic Von Frey, Impactometers, Pinch interdigital Web) -Electrical stimulation cutaneous, RIII reflex -Ischemic tourniquet -hypotonic water injection | Inflammatory | UV erythema Skin freezing NGF* injection IM/SC |
| | | Neuropathic | Capsaicin intradermal Capsaicin topical+heat Repeated electric stimulation by needles/microdialysis probes Transdermal Electric Stimulation (being validated) |
| | | | |
| Visceral | Barostat Oesophagal distension or electric stimulation Bladder instillation of KCl and capsaicin | *:no suitable soi | BIOTRIAL urcing found with ANSM requirements |

Alternatives to self- assessment of pain for R&D

- fMRI pain matrix activation during (any) painful stimuli (Irene Tracey, David Borsook), effect of hypnotic manipulation
- Evoked potentials
 - Requires rapid signal onset/Offset : fast thermodes or lasers (NdYAG or Erbium)
 - Gamma band seems suitable(Hu) 2012
- EEG changes to painful stimuli by Machine Vector Learning (Gravesen)
- RR changes $Metrodoloris^{TM}$ equipment for surgery (no peer-reviewed papers)

Phase IIa reads: Pain ratings n=50-150 parallel groups

| Single dose | Repeated dose | |
|--|---|--|
| Postoperative morphine sparing in PCA Withdom tooth avulsion Knee arthritis with Moskovitz forced walking test | Oncology morphine sparing Breakthrough pain un patients stabilized with opiates Knee osteoartritis (3 months) Lombosciatalgia Rhumatoid arthritis Post-herpetic neuralgia Painful diabetic neuropathy Chemotherapy induced neuropathy | |
| | « Clever designs » Cross-over in diabetic neuropathy with biopsy, elimination of placebo responders (Merck) Nerve trauma cross-over (Pfizer) | |